BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Staging
7 results:

  • 1. Functional Assessment of Synoptic Pathology Reporting for ovarian cancer.
    Słodkowska J; Cierniak S; Patera J; Kopik J; Baranowski W; Markiewicz T; Murawski P; Buda I; Kozłowski W
    Pathobiology; 2016; 83(2-3):70-8. PubMed ID: 27100104
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Commonest cancers in Pakistan - Findings and Histopathological Perspective from a Premier Surgical Pathology Center in Pakistan.
    Ahmad Z; Idrees R; Fatima S; Uddin N; Ahmed A; Minhas K; Memon A; Fatima SS; Arif M; Hasan S; Ahmed R; Pervez S; Kayani N
    Asian Pac J Cancer Prev; 2016; 17(3):1061-75. PubMed ID: 27039726
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dermatomyositis as paraneoplastic syndrome of peritoneal and ovarian relapse after long-term complete remission in patient with metastatic bilateral breast cancer.
    Murgić J; Prpić M; Kirac I; Camino-Varela AM; Bolanca A; Kusić Z
    Coll Antropol; 2012 Mar; 36(1):325-9. PubMed ID: 22816241
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
    Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. How does negative clinical evaluation of ovarian carcinoma after full course of chemotherapy correlate with second-look laparotomy findings?
    Zorlu CG; Cobanoglu O; Caglar T; Ergun Y; Kuscu E; Alaybeyoglu T
    J Surg Oncol; 1994 Apr; 55(4):255-8. PubMed ID: 8159008
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Strategy for the ovarian cancer treatment].
    Ochiai K
    Gan To Kagaku Ryoho; 1993 Dec; 20(16):2454-60. PubMed ID: 8279841
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC)].
    Takizawa K; Ino Y; Isono T; Sato M; Iguchi T; Takeda Y
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1877-83. PubMed ID: 3109329
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.